The company said that for the three months ended June 30, Diagnostics net revenues increased 36% year-over-year to $42.4 million, while Life Science net revenues declined 22% year-over-year to $25.4 million.

Diagnostics net revenues from molecular products increased 11% compared to the prior-year third quarter, and net revenues from nonmolecular assay products increased 40%.

The firm reported a Q3 net loss of $7.3 million, or a loss of $.16 per share, compared to a net income of $11.7 million, or $.26 per share, in the prior-year quarter.

On June 30, its cash and cash equivalents were $83.5 million, and the firm had $175 million of available borrowing capacity under a $200 million commercial bank credit facility.

In July, South Korea-based SD Biosensor and SJL Partners entered an agreement to acquire Meridian Bioscience in an all-cash transaction valued at approximately $1.53 billion.

In Friday afternoon trading on the Nasdaq, shares of Meridian Bioscience were up more than 2% to $32.47.

SD Biosensor, SJL Partners to acquire Meridian Bioscience
South Korea-based SD Biosensor (SDB) and SJL Partners (SJL) have entered an agreement to purchase diagnostics and life sciences firm Meridian Bioscience...

Meridian Bioscience launches master mixes for stool analysis
Meridian Bioscience has introduced two master mixes to improve the molecular detection of DNA and RNA from crude fecal specimens while allowing room temperature...

Meridian Bioscience releases new master mixes
Meridian Bioscience has released two new master mixes for the detection of DNA and RNA in point-of-care diagnostic tests.

FDA clears Meridian's Curian Campy assay
Meridian Bioscience has received U.S. Food and Drug Administration (FDA) clearance for its Curian Campy assay, a rapid, qualitative, fluorescent immunoassay...

Meridian launches new master mixes
Meridian Bioscience has launched two new master mixes that enable direct detection of DNA or RNA/DNA from urine samples.